Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis
© Lee et al.; licensee BioMed Central Ltd. 2011
Received: 3 March 2011
Accepted: 16 June 2011
Published: 16 June 2011
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis that progresses to destruction of cartilage and bone. Bone marrow (BM) cells have been shown to contribute to this pathogenesis. In this study, we compared differentially expressed molecules in BM cells from RA and osteoarthritis (OA) patients and analyzed abnormal regulatory networks to identify the role of BM cells in RA.
Gene expression profiles (GEPs) in BM-derived mononuclear cells from 9 RA and 10 OA patients were obtained by DNA microarray. Up- and down-regulated genes were identified by comparing the GEPs from the two patient groups. Bioinformatics was performed by Expression Analysis Systemic Explorer (EASE) 2.0 based on gene ontology, followed by network pathway analysis with Ingenuity Pathways Analysis (IPA) 7.5.
The BM mononuclear cells showed 764 up-regulated and 1,910 down-regulated genes in RA patients relative to the OA group. EASE revealed that the gene category response to external stimulus, which included the gene category immune response, was overrepresented by the up-regulated genes. So too were the gene categories signal transduction and phosphate metabolism. Down-regulated genes were dominantly classified in three gene categories: cell proliferation, which included mitotic cell cycle, DNA replication and chromosome cycle, and DNA metabolism. Most genes in these categories overlapped with each other. IPA analysis showed that the up-regulated genes in immune response were highly relevant to the antigen presentation pathway and to interferon signaling. The major histocompatibility complex (MHC) class I molecules, human leukocyte antigen (HLA)-E, HLA-F, and HLA-G, tapasin (TAP) and TAP binding protein, both of which are involved in peptide antigen binding and presentation via MHC class I molecules, are depicted in the immune response molecule networks. Interferon gamma and interleukin 8 were overexpressed and found to play central roles in these networks.
Abnormal regulatory networks in the immune response and cell cycle categories were identified in BM mononuclear cells from RA patients, indicating that the BM is pathologically involved in RA.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis that is often pathogenic and destructive to articular cartilage and bone. To understand the complex pathogenesis and heterogeneous manifestations of autoimmune diseases including RA, DNA microarray has emerged as a powerful tool [1–4]. We have shown in studies investigating the pathogenesis of juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) that DNA microarray can be even more effective when combined with bioinformatics techniques such as gene ontology databases and network pathway analysis software [5, 6].
In RA pathology, fibroblast-like synoviocyte (FLS) has been shown to play an essential role in the chronic inflammation of RA joints . Therefore, a number of gene expression profiling studies have focused on synovial tissue or FLS to understand the aberrant biological pathways that contribute to the pathogenesis of RA . Others have focused on peripheral blood mononuclear cells (PBMC) from RA patients, either by comparing them with PBMC from healthy individuals or from patients with other autoimmune diseases [1, 3]. Of greater interest to us is the accumulating evidence suggesting that abnormalities in the bone marrow (BM) have a significant role in RA inflammation [2, 8, 9].
The BM contains three types of stem cells: hematopoietic stem cells (HSCs), which produce all the mature blood lineages for leukocytes, erythrocytes, and platelets; mesenchymal stem cells, which can differentiate into osteoblasts, chondrocytes, and adipocytes; and endothelial stem cells. The proliferations and differentiations of these heterogeneous cell populations are dependent on the BM microenvironment and are regulated by highly sophisticated networks, either through cell-cell interactions or cytokine networks. Indeed, a remarkable elevation in IL6 and IL8 levels in the BM serum from RA patients has been reported to relate to the synovial proliferation seen in multiple joints . Therefore, BM cells may be where the pathogenesis of RA originates, making the study of their abnormal regulatory networks very important.
In this study, we identify aberrant regulatory networks in BM cells from RA patients by analyzing differentially expressed genes based on their gene expression profiles with those of osteoarthritis (OA) patients. OA patients were chosen because the OA pathology is relatively well understood and the BM cells from these patients are far more readily available than those from healthy subjects.
Materials and methods
Human subjects and ethical considerations
Demographic and rheumatoid arthritis disease characteristics
MTX 6 mg/week
Bucillamine 100 mg/day, MTX 4 mg/week
Actarit 200 mg/day
Bucillamine 100 mg/day
Salazosulfapyridine 1000 mg/day, MTX 6 mg/week
MTX 4 mg/week
MTX 6 mg/week
GeneChip microarray and data analysis
Patient BM were collected and kept at 4°C. All BM-derived mononuclear cells (BMMC) were isolated by using Ficoll-Paque™ Plus (GE Healthcare Biosciences, Tokyo, Japan) gradient centrifugation according to the manufacturer's recommendations. Total RNA from the BMMCs was extracted by using the RNeasy Mini Kit (Qiagen, Tokyo, Japan). A 3 μg sample of total RNA was used for DNA microarray analysis by using GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA). Signal values were obtained according to the manufacturer's instructions and normalized by eliminating the highest and lowest 2% of the data, respectively. Only data with present or marginal detection calls were selected for further analysis. Microarray data have been deposited in NCBIs Gene Expression Omnibus (GEO) and are accessible through GEO series accession number [GSE27390].
Gene ontology and network pathway analysis
Genes were identified as differentially expressed if their mean signal values were at least 50% different between the RA and OA groups. These genes were functionally categorized using Expression Analysis Systematic Explorer (EASE) version 2.0 bioinformatics software . Interactions among the differentially expressed genes in each gene category were investigated by using Ingenuity Pathway Analysis (IPA) version 7.5 . Networks generated by less than 10 uploaded genes were excluded from the analysis.
The false-discovery rate was used to determine statistically significant differences in the mRNA expression levels between the RA and OA groups. The criterion for the statistical significance was q < 0.001.
Gene ontology analysis for differentially expressed genes in RA and OA patients
DNA microarray analysis revealed that 2,674 genes were differentially expressed in BMMC from patients with RA compared with those from patients with OA: 764 out of the 2,674 genes were up-regulated and the remaining 1,910 genes were down-regulated.
Top 15 deviated gene categories of overexpressed genes in rheumatoid arthritis bone marrow compared with osteoarthritis bone marrow
(GO biological process)
(Total = 348)
(Total = 10,937)
response to external stimulus
response to biotic stimulus
response to pest/pathogen/parasite
antigen processing, endogenous antigen via MHC class I
response to stress
intracellular signaling cascade
protein kinase cascade
activation of MAPK
protein amino acid phosphorylation
RNA splicing, via transesterification reactions
Top 15 deviated functional categories of underexpressed genes in rheumatoid arthritis bone marrow compared with osteoarthritis bone marrow
(GO biological process)
(Total = 733)
(Total = 10,937)
mitotic cell cycle
regulation of mitosis
regulation of cell cycle
cell cycle checkpoint
DNA replication and chromosome cycle
DNA dependent DNA replication
EASE of the up-regulated genes identified four major gene categories: response to external stimulus, signal transduction, phosphate metabolism, and RNA splicing, via transesterification reactions (Table 2). Based on EASE scores, response to biotic stimulus (EASE score: 6.47E-10), defense response (1.62E-09), and immune response (9.89E-11) were the three most significant gene categories that corresponded with response to external stimulus. Fifty-six of the 67 genes in response to external stimulus belonged to immune response, which had the lowest EASE score (9.89E-11). The genes in signal transduction corresponded to intracellular signaling cascade, protein kinase cascade, and activation of mitogen-activated phosphate kinase (MAPK). Twenty-six of the 33 genes in phosphate metabolism belonged to protein amino acid phosphorylation. Finally, there were eight genes in RNA splicing, via transesterification reactions.
EASE for the down-regulated genes identified three major gene categories: cell proliferation, DNA replication and chromosome cycle, and DNA metabolism (Table 3). The down-regulated genes were predominantly classified into cell cycle (EASE score: 1.06E-26), mitotic cell cycle (2.78E-37), M phase (3.98E-19), nuclear division (4.40E-19), and mitosis (7.91E-21). These gene categories were arranged hierarchically in cell proliferation, which contains 139 genes. Genes related to regulation of cell cycle also belonged to cell proliferation with significant probability (1.83E-11). Most of the genes in the three major gene categories overlapped.
Up-regulated genes in the category immune response and their corresponding network pathway analysis
The gene category immune response for up-regulated genes and mitotic cell cycle for down-regulated genes had the lowest EASE scores, respectively. The relations among the 56 up-regulated genes and the 97 down-regulated genes in these two gene categories were further analyzed by IPA.
Down-regulated genes in the category mitotic cell cycle and their corresponding network pathway analysis
It is commonly known that autoimmunity plays a pivotal role in the pathology of RA. However, the exact etiology and pathogenesis are poorly understood. Our work, comparing the gene expression profiles of BMMC between RA patients and OA patients by microarray technology and gene ontology analysis, found abnormal immune responses in BMMC. This agrees with accumulating evidence indicating that abnormalities in BM cells may contribute to the pathogenesis of RA . To our knowledge, ours is the first report to combine DNA microarray with bioinformatics for describing gene expression profiles from RA BM cells and for revealing abnormal networks involving immune response- and cell cycle-related molecules in those cells.
Several reports have shown that peripheral blood from SLE patients has remarkably homogenous gene expression patterns and an overexpression of IFI genes [6, 15–17]. The IFN signaling pathway is thought to play an important role in the pathogenesis of SLE. There is also one report of genomically profiled peripheral blood cells from 35 RA patients and 15 healthy controls that found a type I IFN signature in a subpopulation of RA patients . Here, we show that the IFN signaling pathway elevates in the BM cellular network pathway of RA patients similar to that in the peripheral blood of SLE patients, although to a lesser degree. The different IFN effects on RA and SLE may be because cytokines are pleiotropic in their biological activities and that they interact with each other in highly sophisticated networks. Along these lines, the effects of IFNβ treatment on arthritis were reviewed several years ago. An open, phase I study conducted on 12 patients with active RA and another pilot study performed on six children with juvenile RA have both shown that IFNβ treatment is in general well tolerated and leads to improvement . However, two other case reports claim RA can develop after the onset of IFNβ treatment in patients with multiple sclerosis . These suggest IFNβ therapy cannot be used universally to combat the development of arthritis.
Meanwhile, our finding that the MHC class I molecules HLA-E, HLA-F, and HLA-G, TAP, and TAPBP were all overexpressed in the BM cells of RA patients is also novel. All these genes relate to the antigen presentation pathway. For example, up-regulation of HLA-E is considered a potential marker for cancer. Additionally, its expression can confer resistance to NK cell-mediated lysis [19, 20]. HLA-F has been recently reported to be a surface marker for activated lymphocytes , while HLA-G has its highest expression during pregnancy and is thought to play a key role in modulating immune tolerance . There is a recently published study by Prigione et al. that reports a lower concentration of soluble HLA-G in sera may predispose to JIA and soluble HLA-E concentration in synovial fluid correlated with the number of affected joints . Nevertheless, the functions of these molecules in autoimmunity are still unclear and debated. In addition, we found TCR, IFNα, NFkB, p38MAPK, IL8, MyD88, and IFNγ play central roles in the immunoregulatory networks of BMMC in RA. Except for NFkB, we found all these genes to be overexpressed. MyD88, the Toll/IL-1 receptor (TIR)-containing adaptor, is used by almost all Toll-like receptors (TLRs) to activate a common signaling pathway that results in the activation of NFkB to express cytokine genes involved in inflammation, as well as IFN-inducible genes [24, 25]. It is possible the up-regulation of MyD88 has a significant role on the aberrant immune response network seen in BMMC from RA patients. However, our data do not show a complementary up-regulation of TLRs, nor do they confirm that the up-regulation of MyD88 was caused by TLRs. It is interesting that Nagata reported up-regulation of IFN-inducible genes in DNase II-deficient mice, which develop a chronic polyarthritis resembling human RA, and they further found no involvement of a TLR system in the IFNβ gene activation in DNase II-/- embryos . Kawane et al. also recently showed that when BM cells from the DNase II-deficient mice were transferred to the wild-type mice, they developed arthritis . Although the mechanisms of arthritis pathogenesis may be different between mice and humans, these mouse-model data do provide supportive evidence to our report.
Another interesting observation is that underexpressed genes were dominantly related to cell cycle and DNA metabolism. We are the first to report the suppression of cell cycle and DNA metabolism in BM cells from RA patients. Initially, there appear to be several possible mechanisms that can explain this result. One is a therapeutic effect caused by MTX, as MTX acts by inhibiting the metabolism of folic acid, which is needed for the de novo synthesis of the nucleoside thymidine required for DNA synthesis. However, subsequent analysis showed MTX treatment does not correlate with the down-regulated gene expressions (data not shown). Alternatively, we considered the fact the BMMC samples in this study were isolated by using Ficoll-Paque, which may cause nucleated erythroblasts to be miscible in mononuclear cell proportions and thus affect cell cycle. Finally, a high concentration of serum IL6 in BM has been reported in RA patients . This is important because IL6 induces the secretion of hepcidin, a humoral factor regulating intestinal iron absorption and iron storage in microphages [28, 29]. Hepcidin can contribute to low serum iron levels if up-regulated, which can then suppress erythroblast differentiation and proliferation in BM, as iron is a requisite element for this process. Furthermore, Colmegna et al. reported a defective proliferative capacity by peripheral blood hematopoietic progenitor cells from RA patients . They further showed that ATM deficiency in RA patients disrupts DNA repair and renders T cells sensitive to apoptosis . Together with their results and our finding that the ATM signaling pathway is repressed in the immunoregulatory networks of BMMC, we suggest that in RA patients, impairments in their immune response cells originally occur in the BM. However, more work is needed on a number of issues including why cell cycle and DNA metabolism were suppressed in the BM, how this suppression relates to RA, and whether defective BM cells relate to activated-immune responses in RA patients.
According to our unpublished data, the genes expressed in the peripheral blood cells of RA patients that correspond to cell cycle and DNA metabolism were not down-regulated as observed in BM cells, but the down-regulation for those in RNA metabolism- or translation-related genes were found. As all mature blood lineages in peripheral blood are produced from HSCs in the BM, the s abnormality in immune response and suppression of cell cycle in BM may contribute to the pathogenesis of RA.
BM cells from RA patients had abnormal functional networks in immune response and cell cycle when compared with the BM cells from OA patients. Our results suggest that the overexpression of genes that take part in the antigen presentation pathway and IFN signaling contribute to the pathogenesis of RA. Our results also suggest that the underexpression of genes relating to cell cycle in the BM may be a potential pathogenic factor for RA.
ataxia telangiectasia mutated
BM-derived mononuclear cells
cell division cycle
disease-modifying antirheumatic drugs
expression analysis systematic explorer
Gene Expression Omnibus
human leukocyte antigen
hepatocyte nuclear factor
hematopoietic stem cells
ingenuity pathway analysis
juvenile idiopathic arthritis
mitogen-activated protein kinase
major histocompatibility complex
myeloid differentiation primary response gene 88
nuclear factor of kappa light polypeptide
peripheral blood mononuclear cells
systemic lupus erythematosus
TAP binding protein
T cell receptor
We would like to thank Dr. Peter Karagiannis and Dr. Takaji Matsutani for advice on the preparing manuscript. We also thank the general practitioners and patients who participated in this study and Ms. Ozawa for her excellent secretarial support. This work was supported by grants from the Ministry of Health, Labor and Welfare of Japan.
- van Baarsen LG, Bos CL, van der Pouw Kraan TC, Verweij CL: Transcription profiling of rheumatic diseases. Arthritis Res Ther. 2009, 11: 207-10.1186/ar2557.View ArticlePubMedGoogle Scholar
- Nakamura N, Shimaoka Y, Tougan T, Onda H, Okuzaki D, Zhao H, Fujimori A, Yabuta N, Nagamori I, Tanigawa A, Sato J, Oda T, Hayashida K, Suzuki R, Yukioka M, Nojima H, Ochi T: Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. DNA Res. 2006, 13: 169-183. 10.1093/dnares/dsl006.View ArticlePubMedGoogle Scholar
- van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL: Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007, 66: 1008-1014. 10.1136/ard.2006.063412.View ArticlePubMedGoogle Scholar
- Qingchun H, Runyue H, LiGang J, Yongliang C, Song W, Shujing Z: Comparison of the expression profile of apoptosis-associated genes in rheumatoid arthritis and osteoarthritis. Rheumatol Int. 2008, 28: 697-701. 10.1007/s00296-008-0534-7.View ArticlePubMedGoogle Scholar
- Ishikawa S, Mima T, Aoki C, Yoshio-Hoshino N, Adachi Y, Imagawa T, Mori M, Tomiita M, Iwata N, Murata T, Miyoshi M, Takei S, Aihara Y, Yokota S, Matsubara K, Nishimoto N: Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann Rheum Dis. 2009, 68: 264-272. 10.1136/ard.2007.079533.View ArticlePubMedGoogle Scholar
- Lee HM, Mima T, Sugino H, Aoki C, Adachi Y, Yoshio-Hoshino N, Matsubara K, Nishimoto N: Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther. 2009, 11: R1-10.1186/ar2584.View ArticlePubMedGoogle Scholar
- Lipsky PE: Why does rheumatoid arthritis involve the joints?. N Engl J Med. 2007, 356: 2419-2420. 10.1056/NEJMcibr070846.View ArticlePubMedGoogle Scholar
- Hirohata S, Yanagida T, Nampei A, Kunugiza Y, Hashimoto H, Tomita T, Yoshikawa H, Ochi T: Enhanced generation of endothelial cells from CD34+ cells of the bone marrow in rheumatoid arthritis: possible role in synovial neovascularization. Arthritis Rheum. 2004, 50: 3888-3896. 10.1002/art.20729.View ArticlePubMedGoogle Scholar
- Ochi T, Yoshikawa H, Toyosaki-Maeda T, Lipsky PE: Mesenchymal stromal cells. Nurse-like cells reside in the synovial tissue and bone marrow in rheumatoid arthritis. Arthritis Res Ther. 2007, 9: 201-10.1186/ar2105.View ArticlePubMedGoogle Scholar
- Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, Nakagawa S, Ono K: Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol. 1994, 21: 830-835.PubMedGoogle Scholar
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.View ArticlePubMedGoogle Scholar
- Altman RD: Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl. 1991, 27: 10-12.PubMedGoogle Scholar
- EASE: the Expression Analysis Systematic Explorer. [http://david.abcc.ncifcrf.gov/ease/ease.jsp]
- Ingenuity Systems. [http://www.ingenuity.com]
- Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003, 100: 2610-2615. 10.1073/pnas.0337679100.View ArticlePubMedGoogle Scholar
- Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003, 197: 711-723. 10.1084/jem.20021553.View ArticlePubMedGoogle Scholar
- Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP: Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54: 2951-2962. 10.1002/art.22044.View ArticlePubMedGoogle Scholar
- van Holten J, Plater-Zyberk C, Tak PP: Interferon-beta for treatment of rheumatoid arthritis?. Arthritis Res. 2002, 4: 346-352. 10.1186/ar598.View ArticlePubMedGoogle Scholar
- Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, Valvassori L, Mordoh J: Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol. 2008, 32: 633-641.PubMedGoogle Scholar
- Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998, 391: 795-799. 10.1038/35869.View ArticlePubMedGoogle Scholar
- Lee N, Ishitani A, Geraghty DE: HLA-F is a surface marker on activated lymphocytes. Eur J Immunol. 2010, 40: 2308-2318. 10.1002/eji.201040348.View ArticlePubMedGoogle Scholar
- Hunt JS, Petroff MG, McIntire RH, Ober C: HLA-G and immune tolerance in pregnancy. FASEB J. 2005, 19: 681-693. 10.1096/fj.04-2078rev.View ArticlePubMedGoogle Scholar
- Prigione I, Penco F, Martini A, Gattorno M, Pistoia V, Morandi F: HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology. 2011, 50: 966-972. 10.1093/rheumatology/keq418.View ArticlePubMedGoogle Scholar
- Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S: Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol. 2004, 5: 1061-1068. 10.1038/ni1118.View ArticlePubMedGoogle Scholar
- Kawai T, Akira S: Toll-like receptor downstream signaling. Arthritis Res Ther. 2005, 7: 12-19. 10.1186/ar1469.View ArticlePubMedGoogle Scholar
- Nagata S: Rheumatoid polyarthritis caused by a defect in DNA degradation. Cytokine Growth Factor Rev. 2008, 19: 295-302. 10.1016/j.cytogfr.2008.04.009.View ArticlePubMedGoogle Scholar
- Kawane K, Tanaka H, Kitahara Y, Shimaoka S, Nagata S: Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci USA. 2010, 107: 19432-19437. 10.1073/pnas.1010603107.View ArticlePubMedGoogle Scholar
- Kartikasari AE, Roelofs R, Schaeps RM, Kemna EH, Peters WH, Swinkels DW, Tjalsma H: Secretion of bioactive hepcidin-25 by liver cells correlates with its gene transcription and points towards synergism between iron and inflammation signaling pathways. Biochim Biophys Acta. 2008, 1784: 2029-2037.View ArticlePubMedGoogle Scholar
- Ganz T, Nemeth E: Iron sequestration and anemia of inflammation. Sem Hematol. 2009, 46: 387-393. 10.1053/j.seminhematol.2009.06.001.View ArticleGoogle Scholar
- Colmegna I, Diaz-Borjon A, Fujii H, Schaefer L, Goronzy JJ, Weyand CM: Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 990-1000. 10.1002/art.23287.View ArticlePubMedGoogle Scholar
- Shao L, Fujii H, Colmegna I, Oishi H, Goronzy JJ, Weyand CM: Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med. 2009, 206: 1435-1449. 10.1084/jem.20082251.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.